Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul;90(7):1586-1599.
doi: 10.1111/bcp.15949. Epub 2023 Nov 22.

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2

Affiliations

Adopting human factors in early phase and experimental medicine research: A nested pilot study observing controlled human infection with SARS-CoV-2

Helen E Higham et al. Br J Clin Pharmacol. 2024 Jul.

Abstract

Aims: The influence of human factors on safety in healthcare settings is well established, with targeted interventions reducing risk and enhancing team performance. In experimental and early phase clinical research participant safety is paramount and safeguarded by guidelines, protocolized care and staff training; however, the real-world interaction and implementation of these risk-mitigating measures has never been subjected to formal system-based assessment.

Methods: Independent structured observations, systematic review of study documents, and interviews and focus groups were used to collate data on three key tasks undertaken in a clinical research facility (CRF) during a SARS CoV-2 controlled human infection model (CHIM) study. The Systems Engineering Initiative for Patient Safety (SEIPS) was employed to analyse and categorize findings, and develop recommendations for safety interventions.

Results: High levels of team functioning and a clear focus on participant safety were evident throughout the study. Despite this, latent risks in both study-specific and CRF work systems were identified in all four SEIPS domains (people, environment, tasks and tools). Fourteen actionable recommendations were generated collaboratively. These included inter-organization and inter-study standardization, optimized checklists for safety critical tasks, and use of simulation for team training and exploration of work systems.

Conclusions: This pioneering application of human factors techniques to analyse work systems during the conduct of research in a CRF revealed risks unidentified by routine review and appraisal, and despite international guideline adherence. SEIPS may aid categorization of system problems and the formulation of recommendations that reduce risk and mitigate potential harm applicable across a trials portfolio.

Keywords: clinical trials; human factors; methodology; patient safety; translational research.

PubMed Disclaimer

Conflict of interest statement

R.L.R. and S.J. have previously contributed to intellectual property licensed by Oxford University Innovation to AstraZeneca. All authors declared no competing interests for this work.

Figures

FIGURE 1
FIGURE 1
The varieties of human work. Conceptualizing human work is important when considering how outcomes are achieved and what impacts the success and/or safety of the task in hand. Shorrock has described four basic varieties of human work. Work as done is, simply put, what actually happens in the workplace and is best analysed by direct observation; work as imagined is how people think work is done at the frontline and is influenced by various factors including past experience, knowledge of the work that is being undertaken and personal bias; work as disclosed is what people say or write about their work; and work as prescribed is the formal description (usually written, e.g., as an SOP) of how work should be done. The figure depicts the four basic varieties of human work (described by Shorrock 20 ) revealing areas of overlap and of difference for each type.
FIGURE 2
FIGURE 2
The Systems Engineering Initiative for Patient Safety(SEIPS). SEIPS, , , was designed by systems engineers and human factors scientists in collaboration with healthcare providers to be a framework for analysing healthcare systems, examining work processes and designing interventions to improve patient safety.The figure provides an overview of the model with patient at the centre of the healthcare system described within socio‐organizational contexts. Key factors influencing patient safety are divided into people (e.g., clinical teams, family members or the patient themselves), environments (e.g., physical, cultural), tasks (which may involve multiple interdependent teams) and tools and technologies, all of which are influenced in turn by external environmental factors (e.g., regulatory bodies or government policy). The SEIPS model recognizes the adaptive nature of healthcare systems with a feedback loop from outcomes back into the work system. SEIPS 101 describes a series of simplified ways of using SEIPS to analyse work in healthcare. The PETT (People, Environments, Task, Tools and technology) scan is one example which can be used in many contexts to consider facilitators and barriers to safe practice (e.g., to examine tasks involved in a ward round or to analyse a safety incident and consider contributory factors). It was chosen for this study as it was designed to be straightforward to use in any clinical context.

References

    1. Koonrungsesomboon N, Laothavorn J, Karbwang J. Ethical considerations and challenges in first‐in‐human research. Transl Res. 2016;1(177):6‐18. doi:10.1016/j.trsl.2016.05.006 - DOI - PubMed
    1. Lowenstein PR, Lowenstein ED, Castro MG. Challenges in the evaluation, consent, ethics and history of early clinical trials—implications of the Tuskegee ‘trial’ for safer and more ethical clinical trials. Curr Opin Mol Ther. 2009;11(5):481‐484. - PMC - PubMed
    1. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti‐CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355(10):1018‐1028. doi:10.1056/NEJMoa063842 - DOI - PubMed
    1. Rocha JF, Santos A, Gama H, et al. Safety, tolerability, and pharmacokinetics of FAAH inhibitor BIA 10‐2474: a double‐blind, randomized, placebo‐controlled study in healthy volunteers. Clin Pharmacol Ther. 2022;111(2):391‐403. doi:10.1002/cpt.2290 - DOI - PMC - PubMed
    1. Schneider CK, Kalinke U, Löwer J. TGN1412—a regulator's perspective. Nat Biotechnol. 2006;24(5):493‐496. doi:10.1038/nbt0506-493 - DOI - PubMed